Gritstone bio and NCI collaborate to evaluate neoantigen cell therapy + vaccine for mutant KRAS solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Gritstone bio Inc., entered into a clinical trial agreement with NCI to evaluate an autologous T-cell therapy expressing a T-cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a phase I study. The study will be led by Steven A. Rosenberg, chief of the surgery branch at NCI’s Center for Cancer Research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login